Bidirectional Regulation of Motor Circuits Using Magnetogenetic Gene Therapy

Regulating the activity of discrete neuronal populations in living mammals after delivery of modified ion channels can be used to map functional circuits and potentially treat neurological diseases. Here we report a novel suite of magnetogenetic tools, based on a single anti-ferritin nanobody-TRPV1 receptor fusion protein, which regulated neuronal activity in motor circuits when exposed to magnetic fields. AAV-mediated delivery of a cre-dependent nanobody-TRPV1 calcium channel into the striatum of adenosine 2a (A2a) receptor-cre driver mice led to restricted expression within D2 neurons, resulting in motor freezing when placed in a 3T MRI or adjacent to a transcranial magnetic stimulation (TMS) device. Functional imaging and fiber photometry both confirmed focal activation of the target region in response to the magnetic fields. Expression of the same construct in the striatum of wild-type mice along with a second injection of an AAVretro expressing cre into the globus pallidus led to similar circuit specificity and motor responses. Finally, a mutation was generated to gate chloride and inhibit neuronal activity. Expression of this variant in subthalamic nucleus (STN) projection neurons in PitX2-cre parkinsonian mice resulted in reduced local c-fos expression and a corresponding improvement in motor rotational behavior during magnetic field exposure. These data demonstrate that AAV delivery of magnetogenetic constructs can bidirectionally regulate activity of specific neuronal circuits non-invasively in vivo using clinically available devices for both preclinical analysis of circuit effects on behavior and potential human clinical translation.

[1]  J. Friedman,et al.  Magnetogenetic cell activation using endogenous ferritin , 2023, bioRxiv.

[2]  Chunyi Zhou,et al.  Differential remodeling of subthalamic projections to basal ganglia output nuclei and locomotor deficits in 6-OHDA-induced hemiparkinsonian mice. , 2023, Cell reports.

[3]  M. Bikson,et al.  A visual and narrative timeline of US FDA milestones for Transcranial Magnetic Stimulation (TMS) devices , 2021, Brain Stimulation.

[4]  R. Kramer,et al.  Evaluating methods and protocols of ferritin-based magnetogenetics , 2021, bioRxiv.

[5]  N. Boulis,et al.  Chemogenetics: Beyond Lesions and Electrodes , 2021, Neurosurgery.

[6]  A. Nambu,et al.  Subthalamic nucleus stabilizes movements by reducing neural spike variability in monkey basal ganglia , 2021, Nature Communications.

[7]  I. Obeso,et al.  Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson's Disease. , 2020, The New England journal of medicine.

[8]  W. Grill,et al.  Technology of deep brain stimulation: current status and future directions , 2020, Nature Reviews Neurology.

[9]  Yi Shen,et al.  Challenges for Therapeutic Applications of Opsin-Based Optogenetic Tools in Humans , 2020, Frontiers in Neural Circuits.

[10]  F. Georges,et al.  Optogenetic investigation into the role of the subthalamic nucleus in motor control , 2020, bioRxiv.

[11]  Åsa K. Björklund,et al.  Spatio-molecular domains identified in the mouse subthalamic nucleus and neighboring glutamatergic and GABAergic brain structures , 2020, Communications Biology.

[12]  N. Heintz,et al.  Functional Analysis of Distinct Populations of Subthalamic Nucleus Neurons on Parkinson’s Disease and OCD-like Behaviors in Mice , 2020, bioRxiv.

[13]  W. Grill,et al.  Frequency-Specific Optogenetic Deep Brain Stimulation of Subthalamic Nucleus Improves Parkinsonian Motor Behaviors , 2020, The Journal of Neuroscience.

[14]  O Keifer,et al.  Chemogenetics a Robust Approach to Pharmacology and Gene Therapy. , 2020, Biochemical pharmacology.

[15]  Suneil K. Kalia,et al.  Subthalamic suppression defines therapeutic threshold of deep brain stimulation in Parkinson’s disease , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[16]  J. Obeso,et al.  Long-term effect of unilateral subthalamotomy for Parkinson’s disease , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[17]  D. Kätzel,et al.  Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice , 2019, Scientific Reports.

[18]  A. J. Robison,et al.  Emerging role of viral vectors for circuit-specific gene interrogation and manipulation in rodent brain , 2018, Pharmacology Biochemistry and Behavior.

[19]  J. Friedman,et al.  Electromagnetic Regulation of Cell Activity. , 2018, Cold Spring Harbor perspectives in medicine.

[20]  Erik A. Wing,et al.  Excitatory TMS modulates memory representations , 2018, Cognitive neuroscience.

[21]  Hagai Bergman,et al.  Insights into the mechanisms of deep brain stimulation , 2017, Nature Reviews Neurology.

[22]  M. Cenci,et al.  Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson’s disease therapy , 2017, The Journal of clinical investigation.

[23]  Jonathan S. Dordick,et al.  Bidirectional electromagnetic control of the hypothalamus regulates feeding and metabolism , 2016, Nature.

[24]  Cody J. Smith,et al.  Genetically targeted magnetic control of the nervous system , 2016, Nature Neuroscience.

[25]  Xiaoyang Long,et al.  Magnetogenetics: remote non-invasive magnetic activation of neuronal activity with a magnetoreceptor , 2015, Science bulletin.

[26]  Polina Anikeeva,et al.  Wireless magnetothermal deep brain stimulation , 2015, Science.

[27]  Jeremy P. Sauer,et al.  Remote regulation of glucose homeostasis in mice using genetically encoded nanoparticles , 2014, Nature Medicine.

[28]  Staci A. Sorensen,et al.  Anatomical characterization of Cre driver mice for neural circuit mapping and manipulation , 2014, Front. Neural Circuits.

[29]  Á. Pascual-Leone,et al.  Suppression of Motor Cortical Excitability in Anesthetized Rats by Low Frequency Repetitive Transcranial Magnetic Stimulation , 2014, PloS one.

[30]  Jaykaran Charan,et al.  How to calculate sample size in animal studies? , 2013, Journal of pharmacology & pharmacotherapeutics.

[31]  Jonathan S. Dordick,et al.  Radio-Wave Heating of Iron Oxide Nanoparticles Can Regulate Plasma Glucose in Mice , 2012, Science.

[32]  K. Deisseroth,et al.  Optogenetic investigation of neural circuits underlying brain disease in animal models , 2012, Nature Reviews Neuroscience.

[33]  L. Mosconi,et al.  PET/CT in diagnosis of movement disorders , 2011, Annals of the New York Academy of Sciences.

[34]  A. Rezai,et al.  AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial , 2011, The Lancet Neurology.

[35]  Anatol C. Kreitzer,et al.  Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry , 2010, Nature.

[36]  Murtaza Z Mogri,et al.  Optical Deconstruction of Parkinsonian Neural Circuitry , 2009, Science.

[37]  David Eidelberg,et al.  Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial , 2007, The Lancet.

[38]  K. Deisseroth,et al.  Millisecond-timescale, genetically targeted optical control of neural activity , 2005, Nature Neuroscience.

[39]  Jia Luo,et al.  Subthalamic GAD Gene Therapy in a Parkinson's Disease Rat Model , 2002, Science.

[40]  P. R. Jensen,et al.  Generation of a synthetic mammalian promoter library by modification of sequences spacing transcription factor binding sites. , 2002, Gene.

[41]  D. Eidelberg,et al.  Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. , 2001, Human gene therapy.

[42]  Ken Solt,et al.  Optogenetics and Chemogenetics. , 2018, Methods in enzymology.

[43]  M. Kaplitt,et al.  Adeno-associated viral gene delivery in neurodegenerative disease. , 2011, Methods in molecular biology.

[44]  Donald W. Pfaff,et al.  Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain , 1994, Nature Genetics.